GLP-1 Drug Names: Branded & Compounded Options Explained

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists include semaglutide, tirzepatide, retatrutide, liraglutide, dulaglutide, and exenatide—each with distinct mechanisms, dosing schedules, and clinical profiles. These medications work by mimicking glucagon-like peptide-1, a hormone regulating blood sugar and appetite.

Knowing GLP-1 drug names is only the first step. Your genetic makeup, biomarker profile, and metabolic characteristics may influence how your body responds to different agents. PlexusDx emphasizes precision selection, combining drug knowledge with personalized genetic and clinical insights to support more targeted provider conversations.

Major GLP-1 Medications: Branded and Compounded Forms

Branded semaglutide (Ozempic for diabetes, Wegovy for weight loss) is administered weekly via injection. Compounded semaglutide offers similar dosing flexibility at lower cost, sourced from licensed 503A pharmacies. Oral semaglutide (Rybelsus) is taken daily and may suit patients preferring tablets over injections.

Tirzepatide (branded Mounjaro for diabetes, Zepbound for weight management) is a dual GIP/GLP-1 agonist given weekly. Compounded tirzepatide provides equivalent formulations through compounding pharmacies. Retatrutide, a newer triple hormone agonist, remains primarily in clinical development but represents emerging GLP-1 class expansion.

GLP-1 Drug Names and Their Mechanisms: A Comparison Framework

Each GLP-1 drug name corresponds to a specific mechanism and receptor profile. Understanding these differences helps clarify why your provider might recommend one over another based on your clinical history, metabolic markers, and treatment goals.

Drug Name (Brand & Generic)	Route & Frequency	Mechanism	Primary Approved Indications
Semaglutide (Ozempic/Wegovy)	Weekly injection or daily oral	GLP-1 agonist	Type 2 diabetes; weight management
Tirzepatide (Mounjaro/Zepbound)	Weekly injection	Dual GIP/GLP-1 agonist	Type 2 diabetes; weight management
Liraglutide (Saxenda/Victoza)	Daily injection	GLP-1 agonist	Type 2 diabetes; weight management (Saxenda)
Dulaglutide (Trulicity)	Weekly injection	GLP-1 agonist	Type 2 diabetes; cardiovascular benefit
Exenatide (Bydureon)	Weekly injection	GLP-1 agonist	Type 2 diabetes; some weight loss benefit
Retatrutide (investigational)	Weekly injection	Triple GIP/GLP-1/GCG agonist	Weight management; type 2 diabetes (trials)

Why GLP-1 Drug Name Matters: Dosing, Duration, and Onset

Different GLP-1 drug names carry different dosing schedules and pharmacokinetics. Semaglutide and tirzepatide offer convenient weekly dosing; liraglutide and exenatide require daily or weekly injections. Onset of action varies—some agents begin lowering glucose within hours, while sustained weight loss typically emerges over weeks to months.

Your provider considers onset profile and dosing frequency alongside your lifestyle, comorbidities, and medication adherence capacity. Compounded versions of semaglutide and tirzepatide maintain the same active ingredients and dosing schedules as branded counterparts, offering cost-effective alternatives without sacrificing efficacy when sourced from licensed 503A pharmacies.

How Genetic Factors May Influence Your Response to GLP-1 Drug Names

Your response to any GLP-1 drug name—whether semaglutide, tirzepatide, or others—is partly shaped by genetic variations in GLP-1 receptor function, GIP signaling, and metabolism. Key variants like GIPR rs1800437 may provide context for individual variability in weight loss and glucose response.

PlexusDx's Precision Peptide Genetic Test examines predispositions in peptide pathway genes including GIPR, FTO, and MC4R. This test should not be interpreted as predicting exact medication response, but rather as helping provide context that may support a more informed conversation with your healthcare provider about which GLP-1 drug name aligns with your metabolic profile.

Safety Considerations and Provider Guidance for GLP-1 Selection

All GLP-1 drug names carry similar safety profiles: nausea, vomiting, and gastrointestinal disturbances are common early side effects. Rare but serious risks include pancreatitis, thyroid C-cell concerns (primarily animal data), and retinopathy in diabetic patients. Pregnancy, personal thyroid cancer history, and severe renal impairment are contraindications.

Your provider evaluates contraindications, concomitant medications, and your specific clinical goals before recommending a particular GLP-1 drug name. Compounded semaglutide and tirzepatide carry the same safety profile as branded versions but should only be used under medical supervision. Regular monitoring for efficacy and adverse effects remains essential regardless of which GLP-1 medication is selected.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that GLP-1 drug names represent a range of mechanisms and potencies. Your genetic predispositions in GLP-1 receptor expression, GIP signaling capacity, and appetite regulation genes may help provide context for why certain drug names might be discussed by your provider. These insights should be interpreted with a qualified healthcare provider as part of a comprehensive assessment.

The Precision Peptide Genetic Test reveals predispositions in four key pathways: GLP1R (GLP-1 receptor sensitivity), GIPR (GIP co-receptor function), FTO (metabolic regulation), and MC4R (appetite signaling). These variants do not determine which GLP-1 drug name will work best, but they may contextualize your metabolic tendencies and support a more personalized conversation about medication selection.

Understanding GLP-1 drug names alongside your genetic profile empowers you to have deeper, more informed discussions with your provider about why a specific agent—whether branded semaglutide, compounded tirzepatide, or another option—might align with your metabolic and clinical characteristics. Genetic context is one tool among many in precision wellness.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which brand names line up with semaglutide versus tirzepatide?

This post maps semaglutide to Ozempic for diabetes and Wegovy for weight loss, with Rybelsus as the daily oral tablet form. Tirzepatide maps to Mounjaro for diabetes and Zepbound for weight management. The article's point in laying out both generic and brand names is that the same molecule appears under different labels depending on the indication it was approved for.

What makes tirzepatide mechanically different from the other names on this list?

Tirzepatide is the only dual agonist among the established options here, acting on both GIP and GLP-1 receptors, and it is given as a weekly injection. Semaglutide, liraglutide, dulaglutide, and exenatide are all described as GLP-1 agonists acting on the single receptor. The article uses that distinction to explain why drug name and mechanism are worth separating.

Where does retatrutide sit among these GLP-1 drug names?

The post classifies retatrutide as investigational, describing it as a newer triple GIP, GLP-1, and glucagon receptor agonist that remains primarily in clinical development. Its listed indications, weight management and type 2 diabetes, are noted as trial settings rather than approvals. It is presented as an example of where the class may expand, not as something available to prescribe today.

Which GLP-1 names on this list are daily rather than weekly?

The article lists liraglutide, sold as Saxenda and Victoza, as a daily injection, and oral semaglutide, sold as Rybelsus, as a daily tablet that may suit people who prefer not to inject. Semaglutide injection, tirzepatide, dulaglutide, and exenatide are all listed as weekly. The post says providers weigh dosing frequency against lifestyle and adherence capacity.

Which risks does this article say apply across every GLP-1 drug name?

The post says nausea, vomiting, and gastrointestinal disturbance are common early side effects across the class. It lists pancreatitis, thyroid C-cell concerns drawn primarily from animal data, and retinopathy in diabetic patients as rare but serious risks. Pregnancy, a personal history of thyroid cancer, and severe renal impairment are named as contraindications regardless of which agent is chosen.

Related Reading

• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1
• Henry Meds Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.